Abbvie-Header Abbvie-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Epirium

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 for the Treatment of Duchenne and Becker Muscular Dystrophy

              Contact the Supplier

              Lead Product(s): Epicatechin

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 14, 2020

              Details:

              The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.

              InGeneron

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function

              Contact the Supplier

              Lead Product(s): Autologous adipose-derived regenerative cells

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 07, 2020

              Details:

              Study reveals favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

              PharmaCompass__DigitalAd